Lifitegrast, sold under the brand name Xiidra (/ˈzaɪdrə/[2]), is a medication for the treatment of signs and symptoms of dry eye, a syndrome called
keratoconjunctivitis sicca. Lifitegrast reduces
inflammation by inhibiting inflammatory cell binding.[3] It is often used in conjunction with
ciclosporin (Ikervis, Restasis, or Cequa) for dry eye treatment including
meibomian gland dysfunction and inflammatory dry eye.
Adverse effects
Common side effects in
clinical trials were eye irritation, discomfort, blurred vision, and
dysgeusia (a distortion of the sense of taste).[4]
Lifitegrast was initially designed by Sunesis and developed by SARcode Bioscience[6] which was acquired by
Shire in 2013,[7] which submitted a
new drug application to the
US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016; approval was granted on 11 July 2016.[8][9] Lifitegrast was approved by Health Canada in January 2018, and available in Canadian pharmacies as of March 2018.
Shire was acquired by
Takeda Pharmaceutical Company in late 2018.[10] In May 2019
Novartis reached an agreement to purchase the assets associated with Lifitegrast. Novartis will pay Takeda an upfront payment of $3.4 billion, while the latter drugmaker is eligible for milestone payments of as much as $1.9 billion. Novartis noted that the drug amassed approximately $400 million in revenue in 2018.[11] In 2023, Novartis sold the assets to
Bausch + Lomb for $1.75 billion and eligible for an additional $750 million in payments linked to future sales for Xiidra as well as two pipeline assets.[12][13]